Company: INDP
Filing Date: 2025-03-27
Form Type: DRS
Source: 0001641172-25-000975
Chunk: 12

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-27
Form: DRS
Chunk 12
---
 over-the-counter (OTC) market during the pendency of the Hearings Panel’s review.

Standby Equity Purchase Agreement with YA

On February 12, 2025, we entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD., a Cayman Islands exempt limited company, (“Yorkville”). Pursuant to the SEPA, we have the right, but not the obligation, to sell to Yorkville from time to time, each such occurrence, an Advance, up to $20.0 million (the “Commitment Amount”) of our common stock, during the 36 months following the execution of the SEPA, subject to the restrictions and satisfaction of the conditions in the SEPA. At our option, the shares of common stock would be purchased by Yorkville from time to time at a price equal to 97% of the lowest of the three daily VWAPs (as hereinafter defined) during a three consecutive trading day period commencing on the date that we, subject to certain limitations, delivers a notice to Yorkville that we are committing Yorkville to purchase such shares of common stock (the “Advance Shares”). We may also specify a certain minimum acceptable price per share in each Advance. “VWAP” means, for any trading day, the daily volume weighted average price of our shares of common stock for such trading day on the Nasdaq Stock Market during regular trading hours as reported by Bloomberg L.P. As consideration for Yorkville’s irrevocable commitment to purchase our shares of common stock up to the Commitment Amount, we issued 305,960 shares of common stock to Yorkville (the “Commitment Shares”). As of the date of this prospectus, we have issued an aggregate of 1,400,000 shares of common stock as Advance Shares to Yorkville for aggregate gross proceeds of approximately $1.1 million.

Company Information

Our principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, NY 10019 and our telephone number is (646) 427-2727. Our website address is http://www.indaptusrx.com. The information contained on, or that can be accessed through, our website is neither a part of nor incorporated into this Registration Statement. We have included our website address in this Registration Statement solely as an inactive textual reference.

| 4 |

<div align='center'>The Offering</div>

| Shares                                             
 of Common Stock Outstanding Prior to this Offering |